Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector

Cancer Gene Therapy

Volumn 10, Issue 11, 2003, Pages 814-822

  Rubinchik, Semyon ^a   Yu, Hong ^a   Woraratanadharm, Jan ^a   Voelkel Johnson, Christina ^a   Norris, James S ^a   Dong, Jian Yun ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GenPhar Inc   (United States)

^c BSB 201 ^*  (United States)

Author keywords

Apoptosis; Brain tumor; Complex adenovirus; Fas ligand; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; FAS LIGAND; FAS LIGAND GREEN FLUORESCENT PROTEIN; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASTROCYTOMA; BRAIN NEOPLASMS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASES; CELL LINE; FAS LIGAND PROTEIN; GENE THERAPY; GENETIC VECTORS; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMINESCENT PROTEINS; MEMBRANE GLYCOPROTEINS; PROTEIN ISOFORMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE;

EID: 0242691851     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700651     Document Type: Article

References (65)

1. Alemany R, Gomez-Manzano C, Balague C, et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 1999;252:1-12.
2. Qureshi NH, Chiocca EA. A review of gene therapy for the treatment of central nervous system tumors. Crit Rev Oncog. 1999;10:261-274.
3. Hong YK, Joe YA, Yang YJ, et al. Potentials and limitations of adenovirus-p53 gene therapy for brain tumors [In Process Citation]. J Korean Med Sci. 2000;15:315-322.
4. Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery. 1999;45:1093-1104.
5. Rizk NP, Chang MY, El Kouri C, et al. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer. Cancer Gene Ther. 1999;6:291-301.
6. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308.
7. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
8. de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastas Rev. 2001;20:51-56.
9. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
10. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci. 1998;23:74-79.
11. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 2001;13:389-400.
12. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 1997;410:96-106.
13. Russell JH. Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol. 1995;7:382-388.
14. Squier MK, Cohen JJ. Cell-mediated cytotoxic mechanisms. Curr Opin Immunol. 1994;6:447-452.
15. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas figand in immune privilege and tumour counter attack. Immunol Cell Biol. 2002;80:131-137.
16. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260.
17. Song Z, Steller H. Death by design: mechanism and control of apoptosis. Trends Cell Biol. 1999;9:M49-52.
18. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev. 2000;64:821-846.
19. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
20. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 2002;13:199-207.
21. Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001;20:4101-4106.
22. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001;6:191-197.
23. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity. 2003;18:1-6.
24. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002;9:164-172.
25. Shinoura N, Yoshida Y, Sadata A, et al. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther. 1998;9:1983-1993.
26. Hedlund TE, Meech SJ, Srikanth S, et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999;6:175-182.
27. Kawaguchi S, Mineta T, Ichinose M, Masuoka J, Shiraishi T, Tabuchi K. Induction of apoptosis in glioma cells by recombinant human Fas ligand. Neurosurgery. 2000;46:431-438; discussion 438-439.
28. Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;97:458-465.
29. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther. 2000;2:348-358.
30. Rubinchik S, Wang D, Yu H, et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther. 2001;4:416-426.
31. Rubinchik S, Ding R, Qiu AJ, Zhang F, Dong J. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther. 2000;7:875-885.
32. Morelli AE, Larregina AT, Smith-Arica J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol. 1999;80:571-583.
33. Aoki K, Akyurek LM, San H, et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy [In Process Citation]. Mol Ther. 2000;1:555-565.
34. Ambar BB, Frei K, Malipiero U, et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther. 1999;10:1641-1648.
35. Lin T, Huang X, Gu J, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene. 2002;21:8020-8028.
36. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther. 2001;4:257-266.
37. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate. 1998;36:92-101.
38. Rokhlin OW, Hostager BS, Bishop GA, et al. Dominant nature of the resistance to Fas- and tumor necrosis factor-alpha-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997;57:3941-3943.
39. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict [In Process Citation]. Ann NY Acad Sci. 2000;910:178-192; discussion 193-175.
40. Rubinchik S, Norris JS, Dong JY. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol. 2002;346:529-547.
41. Rubinchik S, Woraratanadharm J, Schepp J, Dong JY. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods Mol Med. 2003;76:167-199.
42. Schneider EM, Menzl I, Weber O, Hug H. Differential calcium response in HeLa and HeLa-Fas cells by cytotoxic T lymphocytes. Biochem Biophys Res Commun. 2003;301:159-166.
43. Holmstrom TH, Tran SE, Johnson VL, Ahn NG, Chow SC, Eriksson JE. Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 1999;19:5991-6002.
44. Yotsuyanagi H, Shintani Y, Moriya K, et al. Regulation of Fas gene expression in HeLa cells as determined by modified RT-PCR. Cell Mol Life Sci. 1998;54:186-190.
45. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268:1766-1769.
46. Davison E, Kirby I, Whitehouse J, Hart I, Marshall JF, Santis G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med. 2001;3:550-559.
47. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268:382-390.
48. Kim PK, Mahidhara R, Seol DW. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist Updat. 2001;4:293-296.
49. Kruidering M, Evan GI. Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life. 2000;50:85-90.
50. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
51. Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol. 2000;165:3023-3030.
52. Kim JY, Kim YH, Chang I, et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene. 2002;21:3139-3148.
53. Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 2002;62:1583-1587.
54. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993;72:3502-3514.
55. Phillips PC. Antineoplastic drug resistance in brain tumors. Neurol Clin. 1991;9:383-404.
56. Robe PA, Princen F, Martin D, et al. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3′,5′-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. Biochem Pharmacol. 2000;60:241-249.
57. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 1998;5:1705-1711.
58. Wildner O. In situ use of suicide genes for therapy of brain tumours. Ann Med. 1999;31:421-429.
59. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7:867-874.
60. Kirn DH. A tale of two trials: selectively replicating herpesviruses for brain tumors. Gene Ther. 2000;7:815-816.
61. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol. 1996;156:13-17.
62. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene. 2001;20:5789-5798.
63. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest. 1994;94:954-964.
64. Lee SH, Shin MS, Lee JY, et al. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol. 1999;188:207-212.
65. Kimura K, Gelmann EP. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem. 2000;275:8610-8617.